BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease

MELVILLE, N.Y., Jan. 09, 2017, BRTX, (GLOBE NEWSWIRE) BioRestorative Therapies, Inc. ( BRT or the “Company ) (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to seek clearance to commence a clinical trial using its lead cell therapy candidate, BRTX-100, to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. BRTX-100 is a product
http://bit.ly/2iW94at